This study evaluates the efficacy and safety of 3 months of malaria chemoprevention
post-discharge using dihydroartemisinin piperaquine (DHA-P) in children under 5 years of age
admitted with severe anemia. One half will receive monthly DHA-P and the other half placebo.
Phase:
Phase 3
Details
Lead Sponsor:
Liverpool School of Tropical Medicine
Collaborators:
Kenya Medical Research Institute Makerere University The Research Council of Norway